Multitarget-directed ligands: Innovative chemical probes and therapeutic tools against Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 11, Issue 22, 2011, Pages 2797-2806

  Bolognesi, Maria Laura ^a   Simoni, Elena ^a   Rosini, Michela ^a   Minarini, Anna ^a   Tumiatti, Vincenzo ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Carbacrine; Lipocrine; Memoquin; Multifactorial diseases; Multifunctional compounds; Multitarget directed ligands (MTDLs); Neurodegenerative diseases

Indexed keywords

ANTIOXIDANT; BENZOQUINONE DERIVATIVE; BIS(7)TACRINE; CHOLINESTERASE INHIBITOR; LIGAND; LIPOCRINE; MEMOQUIN; MULTITARGET DIRECTED LIGAND; TACRINE DERIVATIVE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; DRUG STRUCTURE; HUMAN;

ACETYLCHOLINESTERASE; ALKANES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ENZYME INHIBITORS; ETHYLAMINES; HUMANS; LIGANDS; TACRINE; THIOCTIC ACID;

EID: 82055186668     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798184373     Document Type: Article

References (85)

1. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov., 2009, 8, 959-968.
2. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol., 2010, 9, 702-716.
3. Ebert, B. Discontinued drugs 2007: Central and peripheral nervous system drugs. Expert Opin. Investig. Drugs, 2009, 18, 109-123.
4. Becker, R. E.; Greig, N. H.; Giacobini, E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J. Alzheimers Dis., 2008, 15, 303-325.
5. Pardridge, W. M. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement., 2009, 5, 427-432.
6. Shineman, D. W.; Fillit, H. M. Alzheimer's disease drug discovery: Abeta and beyond. Curr. Alzheimer Res., 2010, 7, 188-189.
7. Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med., 2010, 362, 329-344.
8. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
9. Morphy, R.; Rankovic, Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 587-600.
10. Van der Schyf, C. J.; Youdim, M. B. Multifunctional drugs as neurotherapeutics. Neurotherapeutics, 2009, 6, 1-3.
11. Millan, M. J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics, 2009, 6, 53-77.
12. Wong, E. H.; Tarazi, F. I.; Shahid, M. The effectiveness of multitarget agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol. Ther., 2010, 126, 173-185.
13. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
14. Bolognesi, M. L.; Rosini, M.; Andrisano, V.; Bartolini, M.; Minarini, A.; Tumiatti, V.; Melchiorre, C. MTDL design strategy in the context of Alzheimer's disease: From lipocrine to memoquin and beyond. Curr. Pharm. Des., 2009, 15, 601-613.
15. Melchiorre, C.; Andrisano, V.; Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Cavrini, V.; Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem., 1998, 41, 4186-4189.
16. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem., 2005, 48, 360-363.
17. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multitarget- directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 2009, 6, 152-162.
18. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J. Med. Chem., 2008, 51, 4381-4384.
19. Bolognesi, M. L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C. Alzheimer's disease: new approaches to drug discovery. Curr. Opin. Chem. Biol., 2009, 13, 303-308.
20. Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Cavalli, A.; Minarini, A.; Recanatini, M.; Rosini, M.; Tumiatti, V.; Melchiorre, C. Heterocyclic inhibitors of AChE acylation and peripheral sites. Farmaco, 2005, 60, 465-473.
21. Silman, I.; Sussman, J. L. Acetylcholinesterase: 'classical' and 'nonclassical' functions and pharmacology. Curr. Opin. Pharmacol., 2005, 5, 293-302.
22. Castro, A.; Martínez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des., 2006, 12, 4377-4387.
23. Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Melchiorre, C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): A step forward in the treatment of Alzheimer's disease. Mini Rev. Med. Chem., 2008, 8, 960-967.
24. Munoz-Torrero, D. Acetylcholinesterase inhibitors as diseasemodifying therapies for Alzheimer's disease. Curr. Med. Chem., 2008, 15, 2433-2455.
25. Starkov, A. A.; Beal, F. M. Portal to Alzheimer's disease. Nat. Med. 2008, 14, 1020-1021.
26. Smith, M. A.; Perry, G.; Pryor, W. A. Causes and consequences of oxidative stress in Alzheimer's disease. Free Radic. Biol. Med., 2002, 32, 1049.
27. Chong, Z. Z.; Li, F.; Maiese, K. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol., 2005, 75, 207-246.
28. Pratico, D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: The road ahead. Neurobiol. Aging, 2005, 26, 581-583.
29. Butterfield, D. A.; Drake, J.; Pocernich, C.; Castegna, A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol. Med., 2001, 7, 548-554.
30. Zhu, X.; Su, B.; Wang, X.; Smith, M. A.; Perry, G. Causes of oxidative stress in Alzheimer's disease. Cell. Mol. Life Sci., 2007, 64, 2202-2210.
31. Xiong, K.; Cai, H.; Luo, X. G.; Struble, R. G.; Clough, R. W.; Yan, X. X. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp. Brain Res., 2007, 181, 435-446.
32. Coma, M.; Guix, F. X.; Ill-Raga, G.; Uribesalgo, I.; Alameda, F.; Valverde, M. A.; Muñoz, F. J. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol. Aging, 2008, 29, 969-980.
33. Isobe, C.; Abe, T.; Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J. Neurol., 2010, 257, 399-404.
34. Wadsworth, T. L.; Bishop, J. A.; Pappu, A. S.; Woltjer, R. L.; Quinn, J. F. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J. Alzheimers Dis., 2008, 14, 225-234.
35. Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young, S.; Hager, K.; Engel, J.; Munch, G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol. Ther., 2007, 113, 154-164.
36. Pratico, D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: Lights and shadows. Ann. N Y Acad. Sci., 2008, 1147, 70-78.
37. Liu, J. The effects and mechanisms of mitochondrial nutrient alpha- lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem. Res., 2008, 33, 194-203.
38. Perry, G.; Zhu, X.; Moreira, P. I.; Smith, M. A. Altered redox balance in disease: can we change the new equilibria? Ann. Neurol., 2009, 65, 121-123.
39. Bolognesi, M. L.; Cavalli, A.; Bergamini, C.; Fato, R.; Lenaz, G.; Rosini, M.; Bartolini, M.; Andrisano, V.; Melchiorre, C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem., 2009, 52, 7883-7886.
40. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Preformed betaamyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem. Biophys. Res. Commun., 2005, 330, 111-116.
41. Ono, K.; Hirohata, M.; Yamada, M. Alpha-lipoic acid exhibits antiamyloidogenicity for beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun., 2006, 341, 1046-1052.
42. Reddy, P. H.; Beal, M. F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med., 2008, 14, 45-53.
43. Mordente, A.; Martorana, G. E.; Minotti, G.; Giardina, B. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)- 1,4-benzoquinone (idebenone). Chem. Res. Toxicol., 1998, 11, 54-63.
44. Bolognesi, M. L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem., 2007, 50, 4882-4897.
45. Raina, A. K.; Templeton, D. J.; Deak, J. C.; Perry, G.; Smith, M. A. Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Rep., 1999, 4, 23-27.
46. Moreira, P. I.; Siedlak, S. L.; Aliev, G.; Zhu, X.; Cash, A. D.; Smith, M. A.; Perry, G. Oxidative stress mechanisms and potential therapeutics in Alzheimer's disease. J. Neural. Transm., 2005, 112, 921-932.
47. SantaCruz, K. S.; Yazlovitskaya, E.; Collins, J.; Johnson, J.; De- Carli, C. Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease. Neurobiol. Aging, 2004, 25, 63-69.
48. Frid, P.; Anisimov, S. V.; Popovic, N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev., 2007, 53, 135-160.
49. Blazer, L. L.; Neubig, R. R. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: Current progress and future hurdles. Neuropsychopharmacology, 2009, 34, 126-141.
50. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12, 156-160.
51. Korcsmaros, T.; Szalay, M. S.; Böde, C.; Kovacs, I. A.; Csermely, P. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discov., 2007, 2, 1-10.
52. Kozlov, A. V.; Gille, L.; Staniek, K.; Nohl, H. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by twoelectron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch. Biochem. Biophys., 1999, 363, 148-154.
53. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
54. Hardy, J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers Dis., 2006, 9, 151-153.
55. Bartolini, M.; Andrisano, V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem, 2010, 11, 1018-1035.
56. Hunt, C. E.; Turner, A. J. Cell biology, regulation and inhibition of beta-secretase (BACE-1). FEBS J., 2009, 276, 1845-1859.
57. Jakob-Roetne, R.; Jacobsen, H. Alzheimer's disease: From pathology to therapeutic approaches. Angew. Chem. Int. Ed. Engl., 2009, 48, 3030-3059.
58. Panza, F.; Solfrizzi, V.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Vendemiale, G.; Capurso, A.; Imbimbo, B. P. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging, 2009, 26, 537-555.
59. Pimplikar, S. W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol., 2009, 41, 1261-1268.
60. Frautschy, S. A.; Cole, G. M. Why pleiotropic interventions are needed for Alzheimer's disease. Mol. Neurobiol., 2010, 41, 392-409.
61. Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem., 1996, 271, 23646-23649.
62. Portoghese, P. S. Edward E. Smissman-Bristol-Myers Squibb Award Address. The role of concepts in structure-activity relationship studies of opioid ligands. J. Med. Chem., 1992, 35, 1927-1937.
63. Li, W.; Mak, M.; Jiang, H.; Wang, Q.; Pang, Y.; Chen, K.; Han, Y. Novel anti-Alzheimer's dimer Bis(7)-cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics, 2009, 6, 187-201.
64. Fu, H.; Li, W.; Luo, J.; Lee, N. T.; Li, M.; Tsim, K. W.; Pang, Y.; Youdim, M. B.; Han, Y. Promising anti-Alzheimer's dimer bis(7)- tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. Biochem. Biophys. Res. Commun., 2008, 366, 631-636.
65. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-targetdirected drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem., 2007, 50, 6446-6449.
66. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891.
67. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta- Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 2003, 65, 407-416.
68. Holzgrabe, U.; Kapkova, P.; Alptuzun, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin. Ther. Targets, 2007, 11, 161-179.
69. Inestrosa, N. C.; Dinamarca, M. C.; Alvarez, A. Amyloidcholinesterase interactions. Implications for Alzheimer's disease. FEBS J., 2008, 275, 625-632.
70. Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem., 2010, 17, 1825-1838.
71. Perez, L. R.; Franz, K. J. Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease. Dalton Trans., 2010, 39, 2177-2187.
72. Bolognesi, M. L.; Bartolini, M.; Mancini, F.; Chiriano, G.; Ceccarini, L.; Rosini, M.; Milelli, A.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Bis(7)-tacrine derivatives as multitarget-directed ligands: Focus on anticholinesterase and antiamyloid activities. ChemMedChem, 2010, 5, 1215-1220.
73. Frydman-Marom, A.; Rechter, M.; Shefler, I.; Bram, Y.; Shalev, D. E.; Gazit, E. Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew. Chem. Int. Ed. Engl., 2009, 48, 1981-1986.
74. Villaverde, M. C.; Gonzalez-Louro, L.; Sussman, F. The search for drug leads targeted to the beta-secretase: An example of the roles of computer assisted approaches in drug discovery. Curr. Top. Med. Chem., 2007, 7, 980-990.
75. Bartolini, M.; Bertucci, C.; Bolognesi, M. L.; Cavalli, A.; Melchiorre, C.; Andrisano, V. Insight into the kinetic of amyloid beta (1- 42) peptide self-aggregation: Elucidation of inhibitors' mechanism of action. ChemBioChem, 2007, 8, 2152-2161.
76. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-targetdirected coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18, 423-426.
77. Reinke, A. A.; Gestwicki, J. E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: Influence of linker length and flexibility. Chem. Biol. Drug Des., 2007, 70, 206-215.
78. Flaherty, D. P.; Walsh, S. M.; Kiyota, T.; Dong, Y.; Ikezu, T.; Vennerstrom, J. L. Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands. J. Med. Chem., 2007, 50, 4986-4992.
79. Fu, H.; Dou, J.; Li, W.; Cui, W.; Mak, S.; Hu, Q.; Luo, J.; Lam, C. S.; Pang, Y.; Youdim, M. B.; Han, Y. Promising multifunctional anti-Alzheimer's dimer bis(7)-cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 oncurrently. Eur. J. Pharmacol., 2009, 623, 14-21.
80. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badía, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodriguez- Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano [3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J. Med. Chem., 2009, 52, 5365-5379.
81. Elsinghorst, P. W.; Hartig, W.; Goldhammer, S.; Grosche, J.; Gutschow, M. A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques. Org. Biomol. Chem., 2009, 7, 3940-3946.
82. Zhu, Y.; Xiao, K.; Ma, L.; Xiong, B.; Fu, Y.; Yu, H.; Wang, W.; Wang, X.; Hu, D.; Peng, H.; Li, J.; Gong, Q.; Chai, Q.; Tang, X.; Zhang, H.; Li, J.; Shen, J. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and betasecretase. Bioorg. Med. Chem., 2009, 17, 1600-1613.
83. Miller, G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science, 2010, 327, 1309.
84. Mechanism matters. Nat. Med., 2010, 16, 347.
85. Morphy, R.; Rankovic, Z. In: Lead Generation Approaches in Drug Discovery, Z. Rankovic; R. Morphy, Eds.; John Wiley & Sons: Hoboken, New Jersey, 2010, pp. 141-164.